‘It's not that we couldn't have done something earlier. The reason that we're announcing these things now is because as we tried to select approaches, we did it with a view that we needed vaccines with three characteristics: No. 1, they have to be vaccines that can be deployed broadly, globally. No. 2, and this is extremely important, these have to be vaccines that we have reasonable confidence could be effective with just a single dose. No. 3, we wanted to develop vaccines that used technology, platforms that have already been proven to work safely and effectively in people.’
Read here (Sydney Morning Herald, May 27, 2020)
